Company news

BioMarin Pharmaceutical Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

BioMarin Submits New Drug Application to U.S. Food and Drug Administration for Vosoritide to Treat Children with Achondroplasia

August 19, 2020

BioMarin Receives Complete Response Letter (CRL) from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

August 18, 2020

European Medicines Agency Validates BioMarin's Marketing Authorization Application for Vosoritide to Treat Children with Achondroplasia

August 12, 2020

BioMarin Announces Second Quarter 2020 Total Revenue Growth of 11% to $430 million

August 3, 2020

BioMarin Submits Marketing Authorization Application to European Medicines Agency for Vosoritide to Treat Children with Achondroplasia

July 22, 2020

BioMarin to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, August 4 at 4: 30pm ET

July 20, 2020

BioMarin Promotes Company Veteran, Brian R. Mueller, to Executive Vice President, CFO

June 28, 2020

BioMarin to Participate in the Virtual BofA Securities 2020 Napa Biopharma Conference

June 22, 2020

BioMarin Provides Additional Data from Recent 4 Year Update of Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in Late-Breaking Oral Presentation at World Federation of Hemophilia Virtual Summit

June 16, 2020

BioMarin Provides Highlights of 4 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

May 30, 2020

BioMarin Announces Closing of Exercise by Initial Purchasers of Option to Purchase an Additional $50 million of 1.25% Senior Subordinated Convertible Notes due 2027

May 18, 2020

BioMarin Announces Proposed Private Offering of $500 Million of Senior Subordinated Convertible Notes

May 10, 2020

BioMarin Announces Pricing of Upsized $550 Million Senior Subordinated Convertible Notes Offering

May 10, 2020

BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement to Develop Gene Therapies for Rare Genetic Cardiomyopathies

May 2, 2020

BioMarin Announces First Quarter 2020 Total Revenue Growth of 25% to $502 million

April 28, 2020

BioMarin Updates Timing of First Quarter 2020 Financial Results Conference Call and Webcast to Wednesday, April 29 at 4: 15pm ET

April 21, 2020

BioMarin Appoints Global Pharmaceutical Veteran C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive Vice President of Global Manufacturing and Technical Operations, Effective May 4

April 20, 2020

BioMarin to Host First Quarter 2020 Financial Results Conference Call and Webcast on Thursday, April 30 at 4: 30pm ET

April 13, 2020

BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe

April 5, 2020

BioMarin Announces Fourth Quarter and Record Full-year 2019 Financial Results

February 25, 2020

BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020

February 19, 2020

BioMarin Announces CFO Succession

February 2, 2020

BioMarin to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Wednesday, February 26 at 4: 30pm ET

January 28, 2020

BioMarin, Pioneer in Phenylketonuria, to Begin Clinical Trial with BMN 307 Gene Therapy

January 12, 2020

BioMarin Announces New England Journal of Medicine Publishes 3 Years of Follow-up Data in Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A

January 1, 2020

BioMarin Announces Positive Final Results from Placebo-Controlled Phase 3 Data in Children with Achondroplasia Treated with Vosoritide

December 15, 2019

BioMarin Submits Marketing Authorization Application to European Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A

November 20, 2019

BioMarin Announces Cumulative Additional Height Gain of 9.0 cm over 54 months versus Natural History in Children with Achondroplasia Treated with Vosoritide in Phase 2 Study

November 13, 2019

BioMarin to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, October 23 at 4: 30pm ET

October 8, 2019

BioMarin Promotes Lon Cardon, Ph.D. to Chief Scientific Strategy Officer

October 6, 2019

BioMarin to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 1 at 4: 30pm ET

July 15, 2019

BioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of Directors

July 8, 2019

BioMarin Plans Regulatory Submissions for Marketing Authorization of Valoctocogene Roxaparvovec to Treat Severe Hemophilia A in 4Q 2019 in both U.S. and Europe

July 7, 2019

BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia from July 6-10, 2019

June 25, 2019

BioMarin Earns Milestone Payments from Pfizer for TALZENNA® (talazoparib) for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation

June 20, 2019

BioMarin Announces New England Journal of Medicine Publishes Vosoritide Phase 2 Study Showing Sustained Annualized Growth Up to 42 Months in Children with Achondroplasia

June 17, 2019

BioMarin Announces Approval of Vimizim® (elosulfase alfa) in China for Treatment of Morquio A Syndrome

June 3, 2019

BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe

May 27, 2019

BioMarin to Host Conference Call Tuesday, May 28, 2019 to Provide a Valoctocogene Roxaparvovec Phase 2 and Phase 3 Update

May 26, 2019

European Commission Approves Palynziq® (pegvaliase injection) for Treatment of Phenylketonuria (PKU) in Patients Aged 16 Years or Older

May 5, 2019

BioMarin to Host First Quarter 2019 Financial Results Conference Call and Webcast on Thursday, April 25 at 4: 30pm ET

April 1, 2019

← Newer news releases

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 56 decks. Every deck is listed under its year.